Premium
CURRENT PROSPECTS FOR THE CHEMOPREVENTION OF PROSTATE CANCER
Author(s) -
Kirby Roger S.,
McNicholas Tom A.,
Fitzpatrick John M.
Publication year - 2010
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2010.09538.x
Subject(s) - citation , prostate cancer , original research , medicine , library science , cancer , computer science
Unlike other areas of medicine, such as Cardiology and Diabetology, Urology has often been slow to embrace strategies for risk reduction. Currently, Urologists prefer to treat the disease at the stage they encounter it, rather than approaching the problem with a preventative frame of mind. However, a recent publication evaluating the effect of dutasteride on prostate cancer [1] calls this view into question. The current lifetime risk of prostate cancer in the USA is estimated at 16.7% [2]. As the disease is both extremely common and generally slow to progress, potentially it provides a prime target for chemoprevention [3].